Dexcom Inc. is a pioneering leader in continuous glucose monitoring, fundamentally changing diabetes management with its innovative biosensing platforms. The company's diverse product range, including the flagship G7, affordable Dexcom ONE+, and the OTC-targeted Stelo, allows it to address varied patient and market needs globally. Its robust, highly recurring revenue stream is underpinned by medical necessity and strong reimbursement coverage, creating a defensible business model. While Dexcom is successfully expanding its market to cover broader diabetes segments and wellness consumers, it faces the dual challenge of sustaining premium pricing against aggressive competitors and executing a transition to a more consumer-facing, diversified company.